Nestle CEO Says Weight-Loss Drugs No Threat to Coffee Business

Nestle, the world’s largest food company, is not threatened by the rising popularity of weight-loss drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Instead, the company sees opportunities to expand its health science business by providing protein bars, powders, and drinks for people taking GLP-1 agonists, such as Zepbound and Wegovy. The category makes up around 20% of Nestle’s annual sales, which last year reached 94.4 billion Swiss francs ($109.53 billion). The drugs, originally designed to treat type 2 diabetes, have been shown to reduce food cravings and cause the stomach to empty more slowly. However, patients taking the drugs could lose lean muscle mass, which could be countered by increasing protein intake and exercise. Nestle is already seeing increasing demand for protein powders, bars, and drinks, while vitamin and nutritional supplements have potential. The company already has more than 1.5 billion Swiss francs of revenue coming from products that provide nutritional benefits suitable to GLP-1 patients.

Read More @ Reuters

Suggested Reading